Brokerages Set Kailera Therapeutics, Inc. (NASDAQ:KLRA) PT at $42.75

Kailera Therapeutics, Inc. (NASDAQ:KLRA) has earned an average rating of “Moderate Buy” from the eight research firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $42.75.

Several research analysts have weighed in on KLRA shares. Weiss Ratings began coverage on Kailera Therapeutics in a report on Friday, August 14th. They set a “sell (d)” rating on the stock. William Blair assumed coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They set an “outperform” rating on the stock. Jefferies Financial Group assumed coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They issued a “buy” rating and a $48.00 price objective for the company. Leerink Partners began coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They set an “outperform” rating and a $36.00 target price on the stock. Finally, JPMorgan Chase & Co. started coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They issued an “overweight” rating and a $30.00 price target for the company.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of KLRA. California State Teachers Retirement System acquired a new stake in Kailera Therapeutics in the 2nd quarter valued at approximately $309,000. Frazier Life Sciences Management L.P. bought a new position in shares of Kailera Therapeutics during the 2nd quarter worth approximately $24,233,000. Wellington Management Group LLP bought a new position in shares of Kailera Therapeutics during the 2nd quarter worth approximately $64,308,000. Finally, Atlas Venture Life Science Advisors LLC acquired a new stake in shares of Kailera Therapeutics in the second quarter valued at approximately $113,923,000.

Kailera Therapeutics Price Performance

NASDAQ:KLRA opened at $18.44 on Thursday. Kailera Therapeutics has a 12-month low of $16.37 and a 12-month high of $28.23. The business has a fifty day moving average of $19.19. The company has a market cap of $2.39 billion and a price-to-earnings ratio of -0.01.

Kailera Therapeutics (NASDAQ:KLRA) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.35). On average, sell-side analysts predict that Kailera Therapeutics will post -3.89 earnings per share for the current year.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.